386 Million EUR Research Programme on Neurodegeneration Featured at Alzheimer Europe Conference
In 2019, the Neuronet Sessions introduced the projects of the Innovative Medicines Initiative (IMI) neurodegeneration portfolio to a broad audience composed of patients, caregivers, patient associations, researchers and clinicians. This year, we expanded the focus of the event, titled "Working together to address common challenges for European neurodegeneration research". Over the course of four parallel sessions, we showcased the work of IMI neurodegeneration projects on data sharing, ethics and regulatory/HTA interactions, and hosted presentations from early-career investigators working on these projects. In addition we held a roundtable discussion, during which project leaders discussed the challenges experienced by public-private partnerships during the COVID-19 pandemic, and how research will evolve in the critical post-COVID period. We are pleased to provide you with recordings of the 2020 Neuronet Sessions, which were held as part of the 30th Alzheimer Europe Virtual Annual Conference between 20-22 October, under the banner "Dementia in a Changing World". Follow this link to access the recordings: https://www.imi-neuronet.org/2020-virtual/ Neuronet has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant Agreement No 821513. The JU receives support from the European Union's Horizon 2020 research and innovation programme, EFPIA and Parkinson's UK.